Worldwide Clinical Trials | Oncology

Helping to Bring Hematologic Oncology Therapies to Cancer Patients

Hematology-oncology (heme/onc) is a core area of expertise for Worldwide Clinical Trials. Our mission is to accelerate the development of innovative blood cancer therapies from proof-of-concept through market authorization, helping bring promising treatments to patients faster.

Hematology-oncology trials require specialized expertise to navigate complex protocols, evolving standards of care, and unique patient population considerations. Partnering with a CRO that understands these complexities is critical to accelerating development and trial success.

Robust pipeline of heme/onc cancer trials

Global Footprint

- Programs across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa

FDA Designations

- Fast track and accelerated approvals
- We supported the 1st FDA approval for a B-cell Maturation Antigen (BCMA)-directed CAR T in Multiple Myeloma

Next-generation Drug Modalities

- Antibody-drug conjugates (ADCs)
- Multi/bi-specific antibodies
- Small molecule inhibitors
- Cell therapies, incuding CAR T

Indications

- Leukemias (AML, CLL/SLL, CML)
- Lymphomas (DLBCL, FL, MCL, NHL, PTCL)
- Multiple myeloma
- Myelodysplastic syndrome
- Rare indications (AITL, PTCL, MZL)

We understand heme/onc cancer trials

- Complex and multifaceted endpoints (Lugano, ELN, IWG, NCCN, IMWG and MRD)
- Complex disease classification, disease transformation from initial diagnosis (e.g. MDS to AML)
- Patients with significant comorbidities
- Bridging therapy is frequently required
- Complex I/E criteria, wash-out windows and rescue medications
- Competitive clinical trial landscape
- Enrollment challenges and complex trial logistics

35+
Heme/Onc Cancer Studies

3,400+
Patients Enrolled

320+
Investigative Sites

Global Footprint
NA, EU, APAC, LATAM, MENA

What Sets Us Apart

Biotech Mindset Delivered Worldwide

We are purpose built around a biotech mindset that shapes both our partnership philosophy and delivery model, bringing the agility, responsiveness, and focus needed to meet critical oncology development milestones.

Oncology Expertise and Team Continuity

Oncology expertise is embedded across all functions, ensuring studies are led by professionals who understand the complexities of oncology science and trial execution. With an average of 11+ years of oncology experience across key roles and an industry-leading 90%+ retention rate in the oncology business unit, you can expect a seasoned, specialized team supporting your study end to end.

Flexible solutions & best-in-class technologies

Data-centric approach with visual analytics & clinical science


Site relationships with rapid startup

Global footprint: 4,000+ across NA, EU, LATAM, MENA & APAC

Active Next-Gen Oncology Experience


Operating both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge modalities.

Phase




Early Phase · Late Phase · Observational/LTFU

Indication



Solid · Heme

Drug Class



Immuno-Oncology · Other · Targeted Therapy

Worldwide Clinical Trials

Oncology at Worldwide

Worldwide features a dedicated oncology business unit within our full-service global contract research organization. We partner with biopharmaceutical sponsors to deliver expert-led, globally scalable oncology trials across every phase of development. We help sponsors move fast with confidence and scale without disruption.

Contact us to learn how we can support your oncology program from FIH through registration.